Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
在常规临床实践中,伊沙佐米、来那度胺和地塞米松(IRD)方案较来那度胺和地塞米松(Rd)方案在复发/难治性多发性骨髓瘤患者中具有生存获益。
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-020-07732-1
Minarik, Jiri; Pika, Tomas; Radocha, Jakub; Jungova, Alexandra; Straub, Jan; Jelinek, Tomas; Pour, Ludek; Pavlicek, Petr; Mistrik, Martin; Brozova, Lucie; Krhovska, Petra; Machalkova, Katerina; Jindra, Pavel; Spicka, Ivan; Plonkova, Hana; Stork, Martin; Bacovsky, Jaroslav; Capkova, Lenka; Sykora, Michal; Kessler, Petr; Stejskal, Lukas; Heindorfer, Adriana; Ullrychova, Jana; Skacel, Tomas; Maisnar, Vladimir; Hajek, Roman